ArticleYonsei medical journal2022
Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA
Article in Yonsei medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation: Piecing Together the Biomarkers.JACC. Asia · 2023Article
- Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF).Journal of arrhythmia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
purposeAtrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA MATERIALS AND
methodsThis multi-center cohort study retrospectively analyzed AF patients with non-gender CHA
resultsOverall, 2694 patients [56.3±9.5 years; female, 726 (26.9%)] were followed-up for 4.0±2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score ≥1. The ABCD score was superior to non-gender CHA
conclusionThe biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.